Sakar Healthcare Limited (NSE:SAKAR)

Market Cap	17.88B +160.2%
Revenue (ttm)	2.52B +41.3%
Net Income	304.85M +74.2%
EPS	13.70 +72.3%
Shares Out	22.25M
PE Ratio	58.66
Forward PE	36.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,400
Open	788.00
Previous Close	795.90
Day's Range	788.00 - 820.00
52-Week Range	311.00 - 889.95
Beta	0.38
Analysts	Strong Buy
Price Target	930.00 (+15.73%)
Earnings Date	Aug 13, 2026

About Sakar Healthcare

Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analgesic, antihistamine, anthelmintic, anti-malarial, antibacterial, vitamins, antifungal, diuretics, oxytocic, antacid, laxative, anticoagulant, anaestheti...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 342
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SAKAR

Financial Performance

In fiscal year 2026, Sakar Healthcare's revenue was 2.52 billion, an increase of 41.34% compared to the previous year's 1.78 billion. Earnings were 304.85 million, an increase of 74.18%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error